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Objectives. We sought to assess the effects of combined oral
positive inotropic and beta-blocker therapy in patients with severe
heart failure.
Background. Patients with severe, class IV heart failure who
receive standard medical therapy exhibit a 1-year mortality rate
>50%. Moreover, such patients generally do not tolerate beta-
blockade, a promising new therapy for chronic heart failure.
Positive inotropes, including phosphodiesterase inhibitors, are
associated with increased mortality when administered over the
long term in these patients. The addition of a beta-blocker to
positive inotropic therapy might attenuate this adverse effect,
although long-term oral inotropic therapy might serve as a bridge
to beta-blockade.
Methods. Thirty patients with severe heart failure (left ventric-
ular ejection fraction [LVEF] 17.2 6 1.2%, cardiac index 1.6 6 0.1
liter/min per m2) were treated with the combination of oral
enoximone (a phosphodiesterase inhibitor) and oral metoprolol at
two institutions. Enoximone was given at a dose of <21 mg/kg body
weight three times a day. After clinical stabilization, metoprolol
was initiated at 6.25 mg twice a day and slowly titrated up to a
target dose of 100 to 200 mg/day.
Results. Ninety-six percent of the patients tolerated enoximone,
whereas 80% tolerated the addition of metoprolol. The mean
duration of combination therapy was 9.4 6 1.8 months. The mean
length of follow-up was 20.9 6 3.9 months. Of the 23 patients
receiving the combination therapy, 48% were weaned off enoxi-
mone over the long term. The LVEF increased significantly, from
17.7 6 1.6% to 27.6 6 3.4% (p 5 0.01), whereas the New York
Heart Association functional class improved from 4 6 0 to 2.8 6
0.1 (p 5 0.0001). The number of hospital admissions tended to
decrease during therapy (p 5 0.06). The estimated probability of
survival at 1 year was 81 6 9%. Heart transplantation was
performed successfully in nine patients (30%).
Conclusions. Combination therapy with a positive inotrope and
a beta-blocker appears to be useful in the treatment of severe,
class IV heart failure. It may be used as a palliative measure when
transplantation is not an option or as a bridge to heart transplan-
tation. Further study of this form of combined therapy is war-
ranted.
(J Am Coll Cardiol 1998;31:1336–40)
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Chronic heart failure due to left ventricular (LV) systolic
dysfunction is a progressive disease syndrome that continues to
be associated with high rates of morbidity and mortality,
despite recent advances in medical therapy (1–4). In patients
with New York Heart Association (NYHA) functional class IV
heart failure, the 1-year mortality rate exceeds 50% despite
aggressive therapy with angiotensin-converting enzyme (ACE)
inhibitors (2). Long-term beta-adrenergic receptor blockade is
a promising new approach to the treatment of heart failure
(3–8). However, beta-blockers are difficult and often impossi-
ble to use in patients with advanced heart failure (3,9,10), and
consequently very limited data are available in this setting.
Several positive inotropic agents have been used to treat
chronic heart failure; unfortunately, most of them have been
shown to increase mortality (11–13). This effect of long-term
positive inotropic therapy to increase heart failure mortality is
especially apparent in patients with advanced heart failure
(11).
Because neurohormonal activation appears to play a pivotal
role in the progression of disease and mortality in patients with
heart failure (14–16), we postulated that adding a beta-blocker
to a positive inotrope would 1) permit successful initiation and
up-titration of beta-blockade; and 2) prevent the deleterious
effects on survival associated with long-term positive inotropic
therapy.
We describe our experience with the addition of metoprolol
to enoximone (17), an oral phosphodiesterase inhibitor, in a
series of 30 patients with chronic, severe and medically refrac-
tory heart failure. Tolerability and the effects on LV function,
symptoms, hospital admission and survival are reviewed.
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Methods
Patient group. Thirty patients with functional class IV
heart failure due to LV systolic dysfunction were evaluated.
Patients selected for enoximone therapy were either receiving
intravenous inotropes and had failed at least two attempts at
inotrope withdrawal (n 5 18 [60%]) or were too sick and
unstable to tolerate beta-blockade in the opinion of the staff
specialist in heart failure (n 5 9 [30%]). This subset of patients
spent an average of 32 days in the hospital per year, and
ultimately three of them had heart transplants and six could
not be weaned off enoximone or had previously not responded
to a beta-blocker (n 5 3 [10%]). Their available records
between October 1984 and November 1996 were reviewed for
this report. Eighteen of these patients were treated at the
University of Utah and 12 at the University of Colorado. All
patients gave written, informed consent to participate in a
compassionate-use study of enoximone. The consent form was
reviewed and approved by the local Institutional Review
Board. Table 1 presents the selected characteristics of these
patients with heart failure. A left ventricular ejection fraction
(LVEF) was available for all patients at baseline (by echocar-
diography in 2 patients, by LV angiography in 2 patients and by
gated blood pool scan in 26 patients) and for 20 patients at the
time of final analysis (all by gated blood pool scan).
Treatment protocol. There were five phases of treatment:
1) Stabilization of the patient with enoximone: Inpatients were
either slowly weaned from intravenous dobutamine or other
intravenous inotropes, and outpatients were admitted to the
hospital for 36 to 48 h to start oral enoximone. The starting
dose of enoximone was usually 1 to 2 mg/kg body weight per
day in three divided doses. Once ambulation was possible, the
patient was discharged. 2) Optimization of heart failure therapy
as an outpatient: Patients received digitalis, diuretic agents and
vasodilators (mostly ACE inhibitors). 3) Institution of beta-
blockade: Metoprolol was started at 6.25 mg orally twice a day
and then gradually increased to a target dose of 100 to
200 mg/day in two or three divided doses. In a few patients, a
once-daily formulation (Toprol XL, Astra) was used. 4) At-
tempted withdrawal of enoximone: After the patient was stable
on the combination therapy for 2 to 4 months, withdrawal of
enoximone was attempted over a period of 2 to 3 weeks. If the
patient’s condition deteriorated, the dose was restored to its
previous level. 5) Long-term therapy: Patients received either
metoprolol alone or the combination when enoximone could
not be weaned. This phase lasted indefinitely or until heart
transplantation or death.
Statistical analysis. SAS software (SAS Institute) was used
for all statistical analyses. All tests were two-sided, and the
significance level was at 0.05. When appropriate, data are
expressed as the mean value 6 SEM. Paired data (at baseline
and during treatment) were analyzed using the paired t test or,
if the distribution of the paired differences was not normal, by
the sign test.
Survival curves and confidence intervals were estimated
using the actuarial method. Survival data for patients under-
going heart transplantation were censored at the time of
transplantation. The survival curves from the Cooperative
North Scandinavian Enalapril Survival Study (CONSENSUS)
and the Prospective Randomized Milrinone Survival Evalua-
tion (PROMISE) were estimated from published data. Using
the log-rank test, they were compared with the survival data for
our patients.
Results
Treatment tolerability. Twenty-nine (96%) of the 30 pa-
tients tolerated long-term oral enoximone therapy. One pa-
tient was withdrawn from enoximone 5 months after initiation
because of a syncopal episode that occurred at home without
documented arrhythmia. All 18 patients who were receiving
intravenous inotropes at baseline were successfully transi-
tioned to oral enoximone. Twenty-four patients (80%) toler-
ated beta-blockade with metoprolol; five patients did not; and
one patient had a heart transplant before metoprolol could be
started. Of the 23 patients on combination therapy, 11 (48%)
were weaned off enoximone, whereas 12 (52%) were consid-
ered stable on the combination, as assessed by clinical deteri-
oration when enoximone was stopped. The mean dose of
enoximone was 189 6 13 mg/day (range 75 to 300). The mean
dose of metoprolol in the 24 patients who tolerated the drug
was 113 6 9 mg/day (range 37.5 to 200). The patients’ mean
length of time on combination therapy was 9.4 6 1.8 months
(range 0.1 to 38.6). The patients’ mean length of follow-up
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
CONSENSUS 5 Cooperative North Scandinavian Enalapril Survival
Study
EF 5 ejection fraction
LV 5 left ventricle, left ventricular
NYHA 5 New York Heart Association
PROMISE 5 Prospective Randomized Milrinone Survival
Evaluation
Table 1. Baseline Characteristics of 30 Study Patients







NYHA functional class IV 30 (100%)
LVEF (%) 17.2 6 1.2
HR (beats/min) (n 5 28) 101 6 4
PCWP (mm Hg) (n 5 14) 25.2 6 1.5
CI (liter/min per m2) (n 5 14) 1.6 6 0.1
Data presented are mean value 6 SEM or number (%) of patients. CI 5
cardiac index; CMP 5 cardiomyopathy; HR 5 heart rate; IDC 5 idiopathic
dilated cardiomyopathy; LVEF 5 left ventricular ejection fraction; NYHA 5
New York Heart Association; PCWP 5 pulmonary capillary wedge pressure.
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(until December 1, 1996, death or heart transplantation) was
20.9 6 3.9 months (range 0.6 to 82.5).
Effect of treatment on clinical variables. The combination
of metoprolol and enoximone improved LV function and
reduced heart rate (Table 2). The LVEF was obtained after a
mean of 16 6 3 months and improved significantly in the
evaluable patients. As assessed by the NYHA functional
classification, combination therapy improved symptoms with a
decrease in functional class ranking from 4 6 0 to 2.8 6 0.1
(p , 0.0001) (Table 2). On therapy, 5 patients were in
functional class IV, 16 were in class III, 8 were in class II and
1 was in class I. There was also a trend (p 5 0.06) toward
reduction in the number of hospital admissions in the year
after compared with the year before initiation of treatment in
the 12 patients for whom this data were fully available. Before
initiation of therapy, one patient was admitted to the hospital
for 4 continuous months and received intravenous inotropes,
but remained out of the hospital after combined therapy.
Clinical outcome. The clinical outcomes of all 30 patients
are summarized in Table 3. This includes the six patients who
did not have long-term beta-blockade, five of whom had heart
transplants. Six patients died: one from small-cell carcinoma of
the lung, three from worsening heart failure and two with
sudden death. Figure 1 shows the intention-to-treat actuarial
survival curve of the 30 patients. Estimated survival rates (95%
confidence interval) are 96% (88% to 100%) at 6 months, 81%
(64% to 98%) at 1 year and 69% (49% to 90%) at 2 years.
These results are significantly better (p 5 0.01) than those for
the enalapril-treated patients in functional class IV (approxi-
mate 1-year actuarial survival rate 54%) in CONSENSUS (2),
in which enalapril was found to be significantly better than
placebo. Similarly, these results are significantly better (p 5
0.03) than those for the patients in functional class IV who
received standard therapy (approximate 1-year actuarial sur-
vival rate 61%) in PROMISE (11), in which standard therapy
was found to be significantly better than milrinone. Figure 2
shows the estimated survival curves for the three studies.
Discussion
Rationale for use of the combination positive inotrope/beta-
blocker therapy. The increase in mortality associated with
long-term inotropic therapy has been attributed to a proar-
rhythmic effect (11–13,18,19) contributing to an increased rate
of sudden death (20) and to direct myocyte toxicity with
acceleration of disease progression (11,18–22). At the molec-
ular level, this toxicity may be related to cyclic adenosine
monophosphate–mediated calcium overload (23).
Beta-blockers have been shown to attenuate these changes
at the molecular (23) and the cellular (21) level. Substantial
data now support their usefulness in the pharmacologic man-
agement of chronic heart failure (3,6,7,24). Beta-blockers may
also reduce the risk of sudden cardiac death (25) and slow the
heart rate. For these and other reasons, they may be ideal in
attenuating the undesirable side effects of positive inotropes
(26,27). In contrast, phosphodiesterase inhibitors, unlike beta-
receptor agonists, would be expected to retain their positive
inotropic and vasodilator effects in the presence of beta1-
selective blockade, because their site of action is beyond the
beta-adrenergic receptor, and the vasodilator as well as some
positive inotropic effects of endogenous catecholamines are
beta2-receptor mediated. Thus, the addition of a beta-blocker
to a phosphodiesterase inhibitor would be expected to elimi-
nate or attenuate the negative inotropic side effects of the
former and the long-term adverse effects of the latter.
In patients with severe heart failure who do not tolerate
beta-blockers, we chose enoximone as the positive inotropic
agent to be used in combination, because at a low dose it
produces enough improvement in cardiac function to allow for
Figure 1. Survival probability, with 95% confidence limits, for all
patients treated with enoximone and metoprolol.






(mean 6 SEM) p Value
LVEF (%) 20 17.7 6 1.6 27.6 6 3.4 0.01
HR (beats/min) 26 101 6 4 80 6 4 0.0001
NYHA functional class 30 4 6 0 2.8 6 0.1 0.0001
Hospital admissions/yr 12 2.3 6 0.3 1.0 6 0.6 0.06
Abbreviations as in Table 1.
Table 3. Clinical Outcomes of Patients at Time of Last Follow-Up
(mean 20.9 6 3.9 months)
No. (%) of Patients
Alive without heart transplantation 15 (50.0)
Alive with heart transplantation 9 (30.0)
Cardiac death 5 (16.7)
Noncardiac death 1 (3.3)
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the use of the beta-blocker (28,29). The use of a drug such as
enoximone is favored because it is available orally, because it
has been used successfully to wean patients from inotropes
(30) or to bridge them to heart transplantation (31) and
because its mechanism of action has been shown to bypass the
beta-receptor and to produce an inotropic effect even with
beta-blockade (32–34).
In our series of 30 patients, we found that treatment with a
combination of enoximone and metoprolol improved LV
function and NYHA functional class and tended to reduce
hospital admissions. The mortality associated with this regimen
was better than that observed in CONSENSUS for patients
treated with enalapril or in PROMISE for placebo-treated
patients in functional class IV.
Study limitations. The most important limitation of our
study is its retrospective nature, with all the bias that this
introduces and the incomplete set of data. The absence of a
control group does not allow for direct comparisons of survival
curves. Another potential weakness is the use of heart trans-
plantation in 30% of the patients, which may have improved
the estimated survival rates, although these patients were
censored at the time of transplantation. Alternatively, all of
these patients may have required heart transplantation had
they not improved while taking enoximone and metoprolol.
Clinical implications. In patients with end-stage heart fail-
ure, heart transplantation is usually offered as the ultimate
therapeutic option to improve survival. However, many pa-
tients are not candidates for transplantation, and donor organs
are scarce. Our data suggest that combined enoximone/
metoprolol therapy is tolerable and might be a potential and
useful therapy in patients with severe heart failure. However,
larger, prospective trials comparing this therapy with placebo
plus conventional treatment will be required to demonstrate
the effectiveness of this approach. If validated, this therapy
should be cost-effective and might reduce the number of
patients waiting for heart transplantation or delay this eventu-
ality.
We thank Susan Veach and Rebecca Olson for their assistance with technical
support.
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